Analytical Chemistry & Pharmacology

摘要-分析化学和药理学（ACP）共享资源 分析化学和药理学SR（ACP）的目标是支持翻译 通过分析化学开发小分子、纳米颗粒和生物抗癌剂， 药理学基础设施、方法和专业知识。分子治疗学的扩展 计划，开发临床前模型，以评估抗癌药物，新北方的开放 卡罗莱纳癌症医院（NCCH）临床试验部门（CTU）和招聘额外的教员， 美国加州大学洛杉矶分校和卡罗莱纳纳米医学研究所（CINM）创造了应用和 转化药理学服务。本SR由转化肿瘤学和纳米颗粒组成 药物开发倡议（TOND 2 I）实验室和位于NCCH CTU的样品处理实验室。的SR 开发和验证生物溶液中的分析测定，分析样品，进行药代动力学 和药效学分析的数据，并提供专门的方法， 评价载体介导的药剂（例如纳米颗粒、缀合物、抗体药物）的药理学 缀合物）和生物制剂。ACP支持整个UMLCCC的研究，并广泛使用 乳腺癌，分子治疗学，癌细胞生物学，免疫学和临床和转化 研究项目在中国科学院。此外，非加太集团与亚太经合组织区域合作中心有着重要的合作关系。 成员也是卡罗莱纳纳米医学研究所（CINM），卡罗莱纳癌症中心的一部分 纳米技术卓越（C-CCNE）和综合化学生物学和药物发现中心 （CICBDD）、药物输送纳米技术中心（CNDD）和药物基因组学中心 个体化治疗（CPIT）在药学院。目前，14个国家正在使用SR。 研究人员，其中74%是同行评审的癌症中心成员。SR的总预算为 请CCSG提供588，141美元和77，823美元（占总预算的13%）。未来的计划是扩大 研究EMLCCC成员，开发新的药理学方法和平台，并利用资源 本SR旨在招募新型抗癌药物以促进转化和临床开发。

ABSTRACT- Analytical Chemistry and Pharmacology (ACP) Shared Resource The goals of the Analytical Chemistry and Pharmacology SR (ACP) are to support the translational development of small molecule, nanoparticle and biological anticancer agents via analytical chemistry and pharmacologic infrastructure, methodologies and expertise. The expansion of the Molecular Therapeutics Program, development of preclinical models to evaluate anticancer agents, the opening of the new North Carolina Cancer Hospital’s (NCCH) Clinical Trials Unit (CTU) and recruitment of additional faculty members to the UNC LCCC and Carolina Institute for NanoMedicine (CINM) created increased demand for applied and translational pharmacology services. This SR is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab and the sample processing lab located in the NCCH CTU. The SR develops and validates analytical assays in biological solutions, analyzes samples, performs pharmacokinetic and pharmacodynamic analyses of data for small molecule agents and provides specialized methods to evaluate the pharmacology of carrier-mediated agents (e.g. nanoparticle, conjugates, antibody drug conjugates) and biologics. The ACP supports studies throughout the UNC LCCC with extensive use by the Breast Cancer, Molecular Therapeutics, Cancer Cell Biology, Immunology and Clinical and Translational Research programs in the UNC LCCC. In addition, the ACP has significant collaborations with UNC LCCC members that are also part of the Carolina Institute for NanoMedicine (CINM), Carolina Center for Cancer Nanotechnology Excellence (C-CCNE) and the Center for Integrative Chemical Biology and Drug Discover (CICBDD), Center for Nanotechnology in Drug Delivery (CNDD) and the Center for Pharmacogenomics and Individualized Therapy (CPIT) in the UNC School of Pharmacy. The SR is currently being used by 14 investigators, 74% of whom are peer reviewed cancer center members. The total budget for the SR is $588,141 and $77,823 (13% of the total budget) is requested from the CCSG. Future plans are to expand the research of UNC LCCC members, develop novel pharmacologic methods and platforms and use the resources of this SR to recruit novel anticancer agents to UNC translational and clinical development.